Online Registration Guidline
ACRI is specialized in providing Clinical Research Courses like Pg Diploma in clinical CDM and SAS course with guarantee internship in leading CRO’S & 100% Placement.
Reach us at:
Avigna Clinical Research Institute:-
No.33,3rd Floor,15th Cross,
2nd Phase,J.P.Nagar,100ft Ring Road,
Bangalore-560078
080-26588910 / 91-9741600499
http://www.acriindia.com
info@acriindia.com
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Online Learning Guideline process.
ACRI is the only institute to incorporate activity based learning methodology. Our students are placed in highly reputed firms and have been recognized for their extensive knowledge in the field of Clinical Research
Reach us :
acriindia.com/about-acri
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Amway North America today launched an online personalized health assessment to simplify the product selection process for consumers. The NUTRILITE® Supplement Recommender is an easy-to-use scientifically-based tool that identifies tailored options for supplementation.
The Supplement Recommender was developed by a Nutrilite team of research and clinical scientists based on the world's No. 1 selling vitamins and dietary supplements brand’s product portfolio.* It identifies health, lifestyle and behavior measures associated with nutrition and health outcomes to generate three primary individualized supplement recommendations and up to nine other product options for optimal health.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61025-amway-personalized-health-assessment-nutrilite-supplement-recommender
The science of bionics helped the more than 1 million Americans with leg amputations take a giant step forward, as the Rehabilitation Institute of Chicago (RIC) revealed clinical applications for the world’s first thought-controlled bionic leg in this week’s New England Journal of Medicine. This innovative technology represents a significant milestone in the rapidly-growing field of bionics. Until now, only thought-controlled bionic arms were available to amputees.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63339-rehabilitation-institute-of-chicago-first-thought-controlled-bionic-leg
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
In this video shanthala Avigna clinical research student talking about teaching, placement and excellent facility provided to students in all aspects to reach their goal.
Inspired by its surrounding southwestern landscape, the Health Sciences Education Building (HSEB) at The University of Arizona College of Medicine-Phoenix is one of the most innovative construction projects in the United States utilizing predominately recycled copper. Using nearly 6,000 copper panels and more than 10,000 copper parts, this 268,000 square-foot building consists of six stories of administration and faculty offices, lecture halls, learning studios, flexible classrooms, clinical suites, gross anatomy facilities, laboratories and conference rooms.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61608-copper-development-green-sustainability-video-case-study-credit-architects
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
New research has revealed that the use of Antimicrobial Copper surfaces in hospital rooms can reduce the number of healthcare-acquired infections (HAIs) by 58% as compared to patients treated in Intensive Care Units with non-copper touch surfaces. In the United States, 1 out of every 20 hospital patients develops an HAI, resulting in an estimated 100,000 deaths per year. Although numerous strategies have been developed to decrease these infections, Antimicrobial Copper is the only strategy that works continuously, has been scientifically proven to be effective and doesn’t depend on human behavior, according to a recently published study in the SHEA Journal of Infection Control and Hospital Epidemiology.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61120-antimicrobial-copper-surfaces-reduce-healthcare-acquired-infections